At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

Mitolyn is a holistic weight loss supplement inspired by Harvard research, taking a refreshing and science-backed approach to ...

A larger waist circumference is associated with a higher risk of all-cause mortality and decreased life expectancy. Meanwhile ...

Both Mounjaro and Wegovy are GLP-1 receptor agonists. So, GLP-1 is basically usually released after eating, sending a signal to your brain that you’re full up and delaying the e ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

As the use of GLP-1s soars in popularity, diners are wrestling with new restaurant etiquette dilemmas — and adjusting ...

President Trump will sign an executive order that institutes a "most favored nation" policy for prescription drug pricing in a push to lower prices.

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.

A survey shows Gen Z favoring weight loss drugs like Ozempic and Wegovy over exercise and diet for reaching their weight loss ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...